Online inquiry

IVTScrip™ mRNA-Human ANKRD44, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK16126MR)

This product GTTS-WK16126MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ANKRD44 protein. This product can be used in Lymphoid-primed multipotent progenitor cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001195144.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 91526
UniProt ID Q8N8A2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ANKRD44, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK16126MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK25319MR IVTScrip™ mRNA-Human ARHGEF39, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGEF39
GTTS-WK26501MR IVTScrip™ mRNA-Human ARHGAP5, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARHGAP5
GTTS-WK9869MR IVTScrip™ mRNA-Human ADRBK1, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADRBK1
GTTS-WK26257MR IVTScrip™ mRNA-Human ARMC8, (Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARMC8
GTTS-WK11638MR IVTScrip™ mRNA-Human ADGRE3, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADGRE3
GTTS-WK9533MR IVTScrip™ mRNA-Human ADGRB2, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADGRB2
GTTS-WK21331MR IVTScrip™ mRNA-Human AIF1L, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AIF1L
GTTS-WK10199MR IVTScrip™ mRNA-Human AGGF1, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGGF1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW